Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-Based Personalized Cancer Therapeutics

Elegen and Nutcracker Therapeutics to pilot first fully cell-free manufacturing process for RNA-based personalized cancer therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs).

Elegen And Nutcracker Pilot Cell-Free Manufacturing Process For RNA-Based Personalized Cancer Therapeutics - Data Intelligence

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable, according to officials at both companies. As late-stage PCT clinical trials progress and therapy developers work to create the next generation of…

Elegen and Nutcracker Pilot Cell-Free Manufacturing Process for RNA-Based Personalized Cancer Therapeutics

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable, according to officials at both companies. As late-stage PCT clinical trials progress and therapy developers work to create the next generation of…